Related Experiment Video
Updated: Jul 9, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Coronary risk factors in Kawasaki disease treated with additional gammaglobulin
M Miura1, H Ohki, T Tsuchihashi
1Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan. miura@as.email.ne.jp
Insights
Early additional intravenous immunoglobulin (IVIG) infusions may prevent coronary artery lesions (CAL) in Kawasaki disease (KD) patients unresponsive to initial therapy. Prompt treatment is key for Kawasaki disease patients to reduce cardiac complications.
Area of Science:
- Pediatrics
- Cardiology
- Immunology
Background:
- Kawasaki disease (KD) is a leading cause of acquired heart disease in children.
- Coronary artery lesions (CAL) are a significant complication of KD, particularly in non-responders to initial therapy.
- Intravenous immunoglobulin (IVIG) is the standard treatment for KD.
Purpose of the Study:
- To evaluate the efficacy of early additional IVIG in preventing CAL in KD patients with persistent or recrudescent fever after initial IVIG.
- To identify risk factors associated with CAL development in non-responder KD patients.
Main Methods:
- A retrospective study of 44 KD patients treated with additional IVIG for persistent/recrudescent fever.
- Outcomes assessed included CAL by echocardiography and duration of fever (pre- and post-additional IVIG).
- Univariate and multivariate analyses were performed to identify risk factors for CAL.
Main Results:
- The number of febrile days before additional IVIG was the only independent risk factor for CAL in multivariate analysis (≥10 days; OR 7.86).
- Early administration of additional IVIG (before 10 febrile days) was associated with a lower prevalence of CAL.
- Other potential risk factors included post-treatment fever duration, divided initial IVIG doses, WBC count, and CRP levels.
Conclusions:
- Early administration of additional IVIG infusions in initial non-responders may prevent CAL in Kawasaki disease.
- Prompt retreatment within 10 febrile days is crucial for mitigating cardiac sequelae in KD.
- This finding supports timely intervention strategies for Kawasaki disease management.
Aims:
To assess the hypothesis that an additional intravenous gammaglobulin (IVGG) infusion, if administered early, may prevent coronary artery lesions (CAL) in patients with Kawasaki disease (KD) who do not respond to initial IVGG therapy.
Methods:
Forty four KD patients (17 with CAL and 27 without CAL), treated with additional IVGG because of persistent or recrudescent fever after initial IVGG therapy, were studied. Main outcome measures were the presence of CAL by echocardiography and the number of febrile days before and after start of additional IVGG infusion (pre- and post-additional IVGG).
Results:
In univariate analyses, risk factors for CAL were the number of febrile days pre-additional IVGG, the number of febrile days post-additional IVGG, the number of days that initial IVGG was divided over, the white blood cell count pre- and post-additional IVGG, and the C reactive protein concentration pre-additional IVGG. In a multivariate analysis, the only independent risk factor was the number of febrile days pre-additional IVGG (> or =10 days; odds ratio 7.86; 95% CI 1.44 to 42.8; p = 0.02).
Conclusions:
Among KD patients with persistent or recrudescent fever after initial IVGG therapy, administration of additional IVGG before the first 10 febrile days was associated with a decreased prevalence of CAL, when compared with the prevalence in those who were retreated later. An additional IVGG infusion, if administered early, may prevent CAL in initial IVGG non-responders.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care